Geneva, Feb. 13 -- International Clinical Trials Registry received information related to the study (ISRCTN15479264) titled 'A phase II trial of CY-101 in participants with adrenocortical cancer' on Feb. 3.
Study Type: Interventional
Study Design:
Allocation: N/A: single arm study
Masking: Open (masking not used)
Control: Uncontrolled
Assignment: Single
Purpose: Treatment
Primary Sponsor: Cancer Research UK
Condition:
Adrenocortical carcinoma
Cancer
Intervention:
This clinical trial has 2 phases (Phase 2A and Phase 2B). It is a Phase II multi-centre open-label randomized dose-optimisation and single-arm dose expansion trial design
In Phase 2A, a total of 16 evaluable participants (i.e. people for whom the main aims of the trial ...